NOTE 16 – LICENSE AGREEMENTS

As of both December 31, 2025 and December 31, 2024, the Company had nine commercial license and supply agreements outstanding, whereby the Company will receive a royalty or other proceeds from the specified product revenues from the licensor, if and when the underlying products are approved and commercialized or sold via compassionate use or early access programs. No revenues have been received through December 31, 2025 from any of these agreements.